Chào mừng trở lại
Tham gia Cointime
Đăng nhập với email
Đăng nhập với
Đăng ký
Pulmatrix
About
Pulmatrix develops inhaled therapies for the treatment, prevention and transmission of infectious and progressive respiratory diseases.
- 11 - 50
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $14M
- Industries
- Biotechnology,Pharmaceutical,Therapeutics
- Founded date
- Jan 1, 2003
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Pulmatrix is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is initially focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with ABPA, and PUR1800, a narrow spectrum kinase inhibitor in lung cancer. Pulmatrix's product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by achieving optimal local drug concentrations and reducing systemic side effects to improve patient outcomes.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 16, 2015 | Post-IPO Equity | $10M | 1 | — | — | Detail |
| Aug 15, 2011 | Series B | $14M | 1 | — | — | Detail |
| Nov 2, 2009 | Series B | $30.20M | 1 |
ARCH Venture Partners
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
ARCH Venture Partners
|
— | Post-IPO Equity |
